(Total Views: 390)
Posted On: 03/01/2019 5:58:38 PM
Post# of 15624
IMO, US institutional investors are not even going to look at this stock with a share price of less than $5. (most consider any stock under $5 a penny stock). It will probably need a share price significantly higher. To them, just another "pot stock"
They won't look at this stock if they are on the OTC for the obvious reasons. If this stock does an RS on the OTC it will be shorted into oblivion. Not a good risk/reward scenario there at all.
The company will need a tremendous catalyst to maintain a share price close to $5 plus an upgrade to a higher exchange, where they at least have a chance at reasonable valuation based on the potential of their product(s), like any other Biotech.
They also don't want the available shares for purchase too low. That would create too much volatility for many institutional investors
No on an RS without more info on a catalyst able to maintain a share price above $5 for at least a couple of months, or even above $1 for that matter.
IMO... GLTA
They won't look at this stock if they are on the OTC for the obvious reasons. If this stock does an RS on the OTC it will be shorted into oblivion. Not a good risk/reward scenario there at all.
The company will need a tremendous catalyst to maintain a share price close to $5 plus an upgrade to a higher exchange, where they at least have a chance at reasonable valuation based on the potential of their product(s), like any other Biotech.
They also don't want the available shares for purchase too low. That would create too much volatility for many institutional investors
No on an RS without more info on a catalyst able to maintain a share price above $5 for at least a couple of months, or even above $1 for that matter.
IMO... GLTA
(1)
(0)
